Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis
- 22 June 1996
- Vol. 312 (7046), 1563-1566
- https://doi.org/10.1136/bmj.312.7046.1563
Abstract
Objective: To compare the relative risks of serious gastrointestinal complications reported with individual non-steroidal anti-inflammatory drugs. Design: Systematic review of controlled epidemiological studies that found a relation between use of the drugs and admission to hospital for haemorrhage or perforation. Setting: Hospital and community based casecontrol and cohort studies. Main outcome measures: (a) Estimated relative risks of gastrointestinal complications with use of individual drugs, exposure to ibuprofen being used as reference; (b) a ranking that best summarised the sequence of relative risks observed in the studies. Results: 12 studies met the inclusion criteria. 11 provided comparative data on ibuprofen and other drugs. Ibuprofen ranked lowest or equal lowest for risk in 10 of the 11 studies. Pooled relative risks calculated with exposure to ibuprofen used as reference were all significantly greater than 1.0 (interval of point estimates 1.6 to 9.2). Overall, ibuprofen was associated with the lowest relative risk, followed by diclofenac. Azapropazone, tolmetin, ketoprofen, and piroxicam ranked highest for risk and indomethacin, naproxen, sulindac, and aspirin occupied intermediate positions. Higher doses of ibuprofen were associated with relative risks similar to those with naproxen and indomethacin. Conclusions: The low risk of serious gastrointestinal complications with ibuprofen seems to be attributable mainly to the low doses of the drug used in clinical practice. In higher doses ibuprofen is associated with a similar risk to other non-steroidal anti-inflammatory drugs. Use of low risk drugs in low dosage as first line treatment would substantially reduce the morbidity and mortality due to serious gastrointestinal toxicity from these drugs. Because there are no important differences in efficacy, choice of first line treatment with these drugs should be based on their relative toxicity Meta-analysis of the available epidemiological studies shows wide differences between individual drugs in the risk of inducing gastrointestinal bleed- ing and ulcer perforation Of the drugs in common use, ibuprofen and diclofenac rank low in toxicity whereas azapropa- zone, ketoprofen, and piroxicam rank high Some of the differences between drugs may be explained by dose, and the advantage of “low risk” drugs may be lost once their dose is increasedKeywords
This publication has 16 references indexed in Scilit:
- NSAIDs: time to re-evaluate gut toxicityThe Lancet, 1994
- Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugsThe Lancet, 1994
- Variation in the risk of peptic ulcer complications with nonsteroidal antiinflammatory drug therapyArthritis & Rheumatism, 1993
- Nonsteroidal Antiinflammatory Drugs and Gastrointestinal Hospitalizations in Saskatchewan: A Cohort StudyEpidemiology, 1992
- Non-steroidal anti-inflammatory drugs and upper gastrointestinal bleeding, a post-marketing surveillance case-control studyPharmacoepidemiology and Drug Safety, 1992
- Comparison of an Antiinflammatory Dose of Ibuprofen, an Analgesic Dose of Ibuprofen, and Acetaminophen in the Treatment of Patients with Osteoarthritis of the KneeNew England Journal of Medicine, 1991
- Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugsThe Lancet, 1991
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986
- NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND BLEEDING PEPTIC ULCERThe Lancet, 1986